Bulletin from Artimplant AB's Annual Meeting of Stockholders 2009.

VASTRA FROLUNDA, Sweden -- Regulatory News:

Artimplant (STO:ARTIB)

Adoption of financial statements, disposition of result and discharge of directors and officers The financial statements of 2008 were adopted. The annual meeting decided to set off the retained loss of SEK 18,317,205 against the statutory reserve. The directors and officers of the Company were granted discharge.

Election of board members Ingemar Kihlstrom was reelected as chairman of the board and Lennart Ribohn, Anna Malm Bernsten, Wenche Rolfsen Sandsborg and Mats Lindquist were reelected as ordinary board members.

Adoption of fees The annual meeting decided that the fee to the board of directors shall be SEK 280,000 to the chairman and SEK 140,000 to ordinary board members. It was also decided that the fee to the chairman of the audit committee shall be SEK 40,000 and the fee to the other members shall be SEK 20,000 and that the fee to the chairman of the remuneration committee shall be SEK 20,000 and to the other members of the committee SEK 10,000. The audit fee will the upcoming year be in accordance with existing agreement for audit services, SEK 175,000 per year.

Election committee The annual meeting decided that the election committee before the annual meeting of 2009, planned to May 2010, shall be appointed by representatives from the three largest stockholders as of September 30, 2009.

Principles for remuneration to senior management The annual meeting adopted the principles for remuneration to senior management as suggested by the board of directors.

Employee stock options The annual meeting decided to adopt the suggested incentive program.

Change of articles of association The annual meeting adopted the change of articles of association as suggested by the board of directors.

All above decisions were taken unanimously.

The presentation made by the CEO at the annual meeting is available at the Company's web page: http://www.artimplant.com/investors-media/presentations.html

Further information is available at www.artimplant.com. To subscribe to future press releases please go to www.artimplant.com/investors-media/subscribe-to-press-releases.html

About Artimplant Artimplant is a biomaterials company focused on solutions to problems in orthopedic and oral surgery. We restore health through the development, production and marketing of degradable implants that regenerate body functions and improve quality of life. Our products, made from Artelon[R], meet unmet clinical needs and are marketed in a growing number of therapy areas. Artimplant produces implants for treatment of osteoarthritis in hands and feet, for shoulder and other soft tissue injuries as well as oral surgery and veterinary medical applications.

Artimplant is a public company listed on the NASDAQ OMX Stockholm Exchange in the Small Cap segment and in the healthcare sector.

Forward-looking statements This press release contains forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations and to attract and retain qualified professionals; technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

This is information which Artimplant shall make public pursuant to the Swedish Financial Instruments Act and the Swedish Securities Exchange and Clearing Operations Act and/or stock market agreements. Information was made available for publication on May 6, 2009 at 08:45 AM (GMT+1).

This information was brought to you by Cision http://www.cisionwire.com